No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC By Ogkologos - March 3, 2026 166 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SONIA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Researchers Discover Potential Way to Hit Elusive Target in Pancreatic Cancer April 4, 2019 Incorporating sTILs Into PREDICT Substantially Improves the Model’s Ability to Distinguish... May 5, 2026 Saying YES: Inspiring a Diverse Generation of Cancer Scientists October 8, 2020 Delivering Palliative Care by Telehealth Meets the Needs of People with... October 28, 2024 Load more HOT NEWS Foodie Fridays: It’s Cucumber Season! Do Black Lives Matter Less Than Those of Cancer Survivors? Cancer in My Community: The Role of Cancer Screening in Guatemala Nivolumab Improves Survival for Some Patients with Advanced Stomach Cancer
